338 related articles for article (PubMed ID: 36969235)
1. Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer.
Lian B; Chen X; Shen K
Front Immunol; 2023; 14():1164514. PubMed ID: 36969235
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
[TBL] [Abstract][Full Text] [Related]
4. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
5. Cracking a cancer code histone deacetylation in epigenetic: the implication from molecular dynamics simulations on efficacy assessment of histone deacetylase inhibitors.
Dushanan R; Weerasinghe S; Dissanayake DP; Senthilinithy R
J Biomol Struct Dyn; 2022 Mar; 40(5):2352-2368. PubMed ID: 33131428
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.
Hornig E; Heppt MV; Graf SA; Ruzicka T; Berking C
Exp Dermatol; 2016 Nov; 25(11):831-838. PubMed ID: 27792246
[TBL] [Abstract][Full Text] [Related]
8. An ELISA method to assess HDAC inhibitor-induced alterations to P. falciparum histone lysine acetylation.
Hesping E; Skinner-Adams TS; Fisher GM; Kurz T; Andrews KT
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():249-256. PubMed ID: 33279862
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Khan O; La Thangue NB
Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.
Garmpis N; Damaskos C; Garmpi A; Kalampokas E; Kalampokas T; Spartalis E; Daskalopoulou A; Valsami S; Kontos M; Nonni A; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Cancer Genomics Proteomics; 2017; 14(5):299-313. PubMed ID: 28870998
[TBL] [Abstract][Full Text] [Related]
13. HDAC Inhibitors as Novel Anti-Cancer Therapeutics.
De Souza C; Chatterji BP
Recent Pat Anticancer Drug Discov; 2015; 10(2):145-62. PubMed ID: 25782916
[TBL] [Abstract][Full Text] [Related]
14. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
15. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
Munster PN; Thurn KT; Thomas S; Raha P; Lacevic M; Miller A; Melisko M; Ismail-Khan R; Rugo H; Moasser M; Minton SE
Br J Cancer; 2011 Jun; 104(12):1828-35. PubMed ID: 21559012
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma.
Zrimšek M; Kuchaříková H; Draganić K; Dobrovolná P; Heiss Spornberger V; Winkelmayer L; Hassler MR; Lochmanová G; Zdráhal Z; Egger G
Cells; 2022 Aug; 11(15):. PubMed ID: 35954222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
